

Journal homepage: http://www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH

RESEARCH ARTICLE

BIOMARKERS FOR DIAGNOSIS AND DISEASE ACTIVITY ASSESSMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS PRESENTING WITH ARTHRITIS

Prasanth.G*, Sunil RaoPadmaraj*, Riju Mathew*, Vijayakumar.T**

*Medical Research Centre, Yenepoya University Mangalore, **MaheInstititute of Dental Scienes

Manuscript Info Abstract Manuscript History: Systemic lupus erythematosus is one of the autoimmune diseases with complex etiology. Arthritis is one of the commonest manifestations of lupus. Received: 25 February 2015 There are several serological markers available for the differential diagnosis Final Accepted: 22 March 2015 of SLE. This study compared the diagnostic markers Anti nuclear antibody Published Online: April 2015 and Anti ds DNA antibody in untreated SLE patients with Erythrocyte sedimentation rate (ESR) and Complement protein C3 & C4 levels to Key words: identify and analyze the relationship and utility of using the different markers Systemic lupus in conjunction for the diagnosis of lupus arthritis. Erythematosus(SLE), Anti nuclear Antibody(ANA), Anti double strand DNA Antibody(AntidsDNA), Complement 3,4(C3.C4),Hemoglobin(Hb) Erythrocyte Sedimentation rate(ESR), C Reactive protein (CRP), Indirect Immunofluorescence(IIFT),Red cell distribution width (RDW).

Prasanth.G

Copy Right, IJAR, 2015,. All rights reserved

INTRODUCTION

*Corresponding Author

SLE is a complex autoimmune condition characterized by marked breakdown in immunological tolerance 1,2,3. SLE has a wide range of organ involvement with varying degree of severity. One of the features of SLE is the involvement of autoantibodies which form immune complexes and resultant complement activation is considered as the main cause for the deleterious consequences in SLE patients⁴. One of the commonest manifestations of SLE is Arthritis and needs to be differentiated from Rheumatoid arthritis by means of diagnostic tests^{5,6}. As per the American college of Rheumatology (ACR) criteria, Anti nuclear antibody(ANA), Anti Ds DNA antibody and Anti Sm Antibody can be used as serological markers and detection of complement levels would predict the disease activity⁷. Rheumatoid factor which is a serological marker for Rheumatoid arthritis is also occasionally detected in Sle patients. The non specificity of such markers would often lead to misdiagnosis or delayed diagnosis. It is often observed that an increased disease activity during acute phase of SLE would lower the serum complement levels .The resultant immune complex deposition at various organs and the lytic activity of the complement proteins adds to the pathologic manifestations of SLE^{9,10}. Hemoglobin level& Red cell distribution width (RDW) are useful hematological parameters in various autoimmune conditions¹¹. An elevated ESR is usually associated with infectious diseases like tuberculosis or autoimmune conditions like Rheumatoid Arthritis or SLE. It is essential to analyze various diagnostic markers during the acute condition of a disease to identify the relationship between the markers and to assess the utility of the markers in diagnosis. This study considered lupus patients with Arthritis. Correlation between the serological markers, complement levels and hematological parameters were analyzed.

Materials & methods

The study was conducted at Educare Institute of dental Sciences. Fifteen subjects satisfying the ACR criteria were selected for the study. Age and sex matched normal individuals were included as controls.Blood samples were collected after informed consent .The samples were tested for Antinuclear Antibody (Indirect immunofluorescence Euroimmun Germany), Anti ds DNA NcX ELISA(Euroimmun Germany), C3 & C4 complement levels and CRP by Immuno-nephelometry(SiemensBNProspec), Hemoglobin(Sysmex Kx21Autoanalyser).The results were analyzed using SPSS 17 and Minitab 16. P value less than or equal to 0.05 is considered as significant.

Results & Discussion

Thirty six Rheumatoid factor negative subjects with suspected SLE arthritis were tested for the serological, Immunological and hematological parameters. Female subjects constituted -63.6% of the total (fig 1). The descriptive statistics are detailed in Table 1. 45.5% of the total had positive ANA results (fig2) whereas dsDNA Antibody was positive for 37.5% of the total subjects. Twentyeightpercent of the total had low Hb level, 37.5% had decreased complement c3 &28% had low c4 levels. Forty six percent of the total subjects had elevated RDW. Among the patient group all were positive for ANA, 80% for ds DNA & 60% had low Hb levels. The distribution of dsDNA, CRP, RDW and Hb in test and control group is shown in fig 3 &4.CRP levels were elevated in 93% of pateints. Low c3 levels were found in 80% and low C4 levels in 60% of the patients. RDW was elevated in 86 % of the patient group. ANA & Anti ds DNA levels showed negative correlation with complement levels whereas CRP & RDW showed positive correlation(p<0.005)Table 2).

Figure 1. Sex distribution of the study subjects





Figure 2. ANA positivity of the study population



Tabel 1. Descriptive statistics and t test of the study population

Variable	Control (N=39)	Test (N=36)	t Test P value
Age	43.08 ± 11.64	39.47 ± 10.71	0.166 (NS)
Anti DsDNA	63.67 ± 29.76	447.8 ± 254.6	<0.001 (Sig)
C reactive Protein	7.108 ± 4.625	26.89 ± 24.13	<0.001 (Sig)
Hemoglobin	13.864 ± 1.269	11.444 ± 1.443	<0.001 (Sig)
RDW	13.279 ± 1.444	16.719 ± 1.766	<0.001 (Sig)
C3	120.33 ± 22.23	59.39 ± 17.2	<0.001 (Sig)
C4	32.05 ± 9.97	12.972 ± 5.526	<0.001 (Sig)

RDW: Red Cell Distribution Width C3: Compliment C3. C4:Complement C4,

No significant difference in age, but all parameters are statistically highly significant against test and control means.





Figure 3. Anti dsDNA of test and control population

The CRP levels were found to be higher in patients indicating marked inflammatory activity (Figure 4.). *Li etal*had reported reduced CRP levels in Systemic lupus patients compared to Rheumatoid Arthritis subjects ¹² while Independent studies by *Eudy etal* ¹³ & *Pradhanetal* ¹⁴ found higher CRP levels useful in detecting active disease and flare.

Table 2. Correlation Table of the study parameters			
Parameter		ANTI DSDNA	
CRP	r	0.499	
	p	0.001	
НВ	r	-0.535	
	p	0.001	
RDW	r	0.690	
	p	0.001	
C3	r	-0.721	
	p	0.001	
C4	r	-0.714	
	p	0.001	
r: Correlation coefficient, P: Significance			

The patterns of ANA observed were mostly homogenous pattern(66%) & speckled pattern(34%). The Immunoflourescence pattern was graded (Figure 5.). The correlation between the various parameters is explained in Table 2.



The studies by *Li etal* highlighted the utility of complement levels in assessing the disease activity. This study also underlines the fact that a positive autoantibody titre with lowered complement levels indicates active disease. High ds DNA Antibody could also be a predictive marker for the development of lupus nephritis and other complications. Earlier studies have shown that during the early stages of the diseases there may not be a considerable difference in C3, C4 and CRP levels in SLE & Rheumatoid Arthritis patients. A low hemoglobin level and a high RDW is often indicative of anemia in auto immune patients and needs further investigation .Chronic blood loss may also contribute to this condition.SLE causes immune complex deposition in kidneys and other organs and the sustained complement activation results in marked reduction in serum complement levels. High CRP levels were observed among the patient group contrary to the findings of *Li etal and were* correlating well with ds DNA antibody levels suggestive of active disease .*Pradhan etal* ¹³ had reported high CRP levels in north Indian lupus nephritis subjects and recent studies by *Eudy etal* ¹⁴ had reported a stronger association of CRP with flare in SLE subjects.

Conclusion

Systemic lupus patients presenting with Arthritic symptoms clinically resembles Rheumatoid Arthritis.In these Rheumatoid factor negative patients with suspected lupus arthritis, Anti nuclearAntibody, AntidsDNA Antibody can be used as diagnostic markers whereas complement levels can assess the disease activity. The inflammatory marker CRP was elevated in the patient group and needs further investigation to rule out infections or other inflammatory conditions as the role of CRP in active SLE or as a predictive disease activity marker is yet to be established. High dsDNA titres along with elevated CRP might be useful in predictinglupus nephritis while hemoglobin levels and RDW are useful to detect anemia and chronic blood loss.Combined use of these biomarkers helps in early diagnosis and management and reduces the immune complex mediated injury to vital organs.

References

- Chang E, Abrahamowicz M, Ferland D, Fortin P R. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J ClinEpidemiol 2002. 55488–497.497
- 2) Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
- 3) Liang M, Fortin P, Schneider M, et al. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
- 4) Wollaston SJ, Farewell VT, Isenberg DA, et al. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 2004;31:2390-4.
- 5) Rodríguez-Carrio J, Prado C, de Paz B, et al. Circulating endothelial cells and their progenitors in systemic lupus erythematosus and early rheumatoid arthritis patients. Rheumatology (Oxford) 2012;51:1775–1784.
- 6) Ahmed TA, Ikram N, Hussain T, et al. Clinical and laboratory features of systemic lupus erythematosus (SLE) in Pakistani patients. J Pak Med Assoc. 2002;52:12–15.
- 7) Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.
- 8) Almeida Mdo S, Bértolo MB, Da Silva BB, De Deus Filho A, Almeida MM, Veras FF, Mendes LC. Epidemiological study of patients with connective tissue diseases in Brazil. Trop Doct. 2005;35:206–209.
- 9) Michael D. Hughson, Zhi He, Jeffrey Henegar, and Robert McMurray (2001) Alveolar Hemorrhage and Renal Microangiopathy in Systemic Lupus Erythematosus. Archives of Pathology & Laboratory Medicine: April 2001, Vol. 125, No. 4, pp. 475-483.
- 10) Brentjens, J. , E. Ossi , and B. Albini . et al. Disseminated immune deposits in lupus erythematosus. Arthritis Rheum 1977. 20:962–968.
- 11) RDW in patients with systemic lupus erythematosus. Influence of anaemia and inflammatory markers. Vayá A, Alis R, Hernández JL, Calvo J, Micó L, Romagnoli M, Ricarte JM. Clin Hemorheol Microcirc. 2013 Jan 1; 54(3):333-9.
- 12) Li WH, Li H, Song WQ, Hu YL, Liu YH, Da R, Chen XB, Li Y, Ling H, Zhong ZH, Zhang FM. Differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis with complements C3 and C4 and C-reactive protein. ExpTher Med. 2013;6:1271–1276.

- 13) Pradhan, Vandana, et al. "High sensitivity C-reactive protein (hsCRP): Association with clinical subsets in systemic lupus erythematosus (SLE) patients from Western India." *Indian Journal of Rheumatology* 8.2 (2013): 65-67.
- 14) Eudy A, Vines A, Dooley M, Cooper G, Parks C. Elevated C-reactive protein and self-reported disease activity in systemic lupus erythematosus. Lupus. 2014 Jul 23. pii: 0961203314543915. [Epub ahead of print] PubMed PMID: 25057037 [PMC free article] [PubMed]